Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study to Demonstrate the Antiviral Activity and Safety of Dolutegravir in HIV-1 Infected Adult Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.

NCT01328041 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT01328041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01328041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study to Demonstrate the Antiviral Activity and Safety of Dolutegravir in HIV-1 Infected Adult Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Lead sponsor
ViiV Healthcare
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2011
Completion date
May 31, 2015
Enrollment
183 (actual)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

infection, human immunodeficiency virus